skip to content


Istesso announces positive outcome from P1 study

30 August 2017 09:19

IP Group's majority-owned subsidiary Istesso - formerly Modern Biosciences - has announced new data from a cohort of patients dosed as part of a phase 1 study of MBS2320, its investigational drug for the treatment of rheumatoid arthritis. MBS2320 was safe and well-tolerated in these patients, and showed no interaction with background therapy.

In addition, positive trends consistent with MBS2320's mode of action were observed in biomarkers of inflammation and bone metabolism. Chief executive of Istesso and head of biotech at IP Group, Dr Sam Williams, said: "These positive pPhase 1 data from patients are very encouraging.

"We look forward to the results from our ongoing Phase 2a study for MBS2320 late next year and progress with Istesso's other pipeline products which, like MBS2320, reprogramme metabolism to treat autoimmune diseases such as multiple sclerosis, psoriasis and ulcerative colitis."

At 9:19am: (LON:IPO) IP Group PLC share price was -2.05p at 113.05p

Story provided by

Related Company: IPO

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.